First-to-market TLR9 Agonist to Harness the Immune System and Accelerate Wound Healing
The Market:
Globally, it is estimated that 60 million patients suffer from chronic wounds and over 300 million surgical wounds are created every year.1,2
Mortality rates are high due to infection risk and delayed healing.
There is a critical need to accelerate healing.
Patients with surgical infections 5 times more likely to die
No ideal therapeutic exists.3
The Market:
Globally, it is estimated that 60 million patients suffer from chronic wounds and over 300 million surgical wounds are created every year.1,2
Mortality rates are high due to infection risk and delayed healing.
There is a critical need to accelerate healing.
Patients with surgical infections 5 times more likely to die
No ideal therapeutic exists.3
Our Solution:
First-to-market TLR9 agonist that accelerates wound healing by harnessing the immune system and stimulating a cellular response to the injury.
Topical administration optimizes safety and convenience.
Our wound healing development program is fast approaching Investigational New Drug (IND) submission, clearing the path for first-in-human clinical trials in the very near term.
For more information, please download the Investor Presentation
Wounds Are a Major Healthcare Challenge with Poor Mortality and High Costs
These costs are driven largely by infections and delayed healing.
Annual cost for chronic wounds
Annual cost for acute wounds
Patients with surgical infections are
more likely to die
The 5-year mortality is over 300% worse for patients with DFUs than those with breast cancer. 4
The 5-year mortality is over 300% worse for patients with DFUs than those with breast cancer.4
Addressing this Challenge with the First-to-Market, Topically Applied TLR9 Agonist that Harnesses the Immune System to Accelerate Wound Healing
SLOW HEALING
No treatment
SLOW HEALING
Vehicle
ACCELERATED HEALING
Treated with our product
No safety issues identified in this study.
Data generated in a pig model
Our Product Accelerates Healing by Harnessing the Immune System Stimulating a Cellular Response to Injury
This is a first-to-market product with a well understood and validated MOA.
- Topical administration allows for ease of application and additional safety
Receptor Binding: CpG binds to the TLR9 receptor in the cell and stimulates the immune system (i.e., a TLR9 agonist)
Immune Stimulation: release of proinflammatory and other substances
accelerate healing
TLR9 agonists as a class have demonstrated proven long-term safety.
US patent 12,344,846B2 issued July 2025
- Topical administration allows for ease of application and additional safety
Receptor Binding: CpG binds to the TLR9 receptor in the cell and stimulates the immune system (i.e., a TLR9 agonist)
Immune Stimulation: release of proinflammatory and other substances
accelerate healing
TLR9 agonists as a class have demonstrated proven long-term safety.
US patent 12,344,846B2 issued July 2025
- Topical administration allows for ease of application and additional safety
Receptor Binding: CpG binds to the TLR9 receptor in the cell and stimulates the immune system (i.e., a TLR9 agonist)
Immune Stimulation: release of proinflammatory and other substances
accelerate healing
TLR9 agonists as a class have demonstrated proven long-term safety.
US patent 12,344,846B2 issued July 2025
The Overall Path from Development to Commercial Approval is Low-Cost, Straightforward and Derisked.
For more information, please download the Investor Presentation
References:
- Maheshwari, G. (2024), Chronic Wounds: a rising public health concern. Wounds APAC, volume 7, issue 1
- Edwards, J. (2025), The prevention and management of surgical wound complications from acute to community. Wounds UK
- Wan, Y.I. (2021), Postoperative infection and mortality following elective surgery in the International Surgical Outcomes Study (ISOS). BJS, 108, 220-227
- Armstrong, D. (2020), Five-year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. Journal of Foot and Ankle Research https://doi.org/10.1186/s13047-020-00383-2
Proven Team with Over 100 Years Total Development & Commercial Experience
LEADERSHIP
Nyron Khan
Led launches of several major Pharma brands at Roche, Alexion and Alcresta
Co-founder & CEO
Commercial Lead
Nyron Khan
Led launches of several major Pharma brands at Roche, Alexion and Alcresta
Co-founder & CEO
Commercial Lead
Nyron Khan
Led launches of several major Pharma brands at Roche, Alexion and Alcresta
Co-founder & CEO
Commercial Lead
Howard L. Levine, Ph.D.
Proven thought-leader in biopharmaceutical product development and commercialization
Co-founder
CMC Lead
Dr. Simon Talbot
Plastic Surgeon at Mass General Brigham; Associate Professor of Surgery, Harvard Medical School
Chair, SAB
Medical Lead
Tom Biancardi, MBA
Experienced Finance leader with proven track record in fundraising and deal-making. Currently, CFO at Beacon Therapeutics.
Co-founder
Finance Lead
Prashant Girinath, Ph.D., J.D.
Lifesciences attorney at Greenberg Traurig in Boston. Develops IP strategy and counsels on M&A.
Co-founder
Corporate Strategy Lead
ADVISORS
Dr. Ned Swanson
Co-founder, President and Chief Medical Officer of the wound healing company PolarityBio
Clinical Advisor
Dr. Anil Chandraker
Professor and Chief of Renal Medicine at UMass Chan Medical School
Past President of the American Society of Transplantation
Scientific Advisor
(Immunology)
Dr. Alice Bexon
CEO, Bexon Clinical Consulting.
Seasoned drug developer with specific expertise in helping early-stage companies.
Scientific Advisor
(TLR9 Development)
Shohreh Miller, DVM, PhD, DACLAM
Director of In Vivo Services at Rutgers University. Deep expertise in translational science, preclinical development, and laboratory animal medicine.
Scientific Advisor
(Preclinical Studies)